Literature DB >> 17827957

Management of hepatocellular carcinoma.

M De Giorgio1, S Fagiuoli.   

Abstract

The aim of this review was to assess the correct clinical management of hepatocellular carcinoma (HCC). Following the diagnosis, the correct choice of treatment must take into account both the anatomical/biological features of HCC and the functional status of the underlying cirrhosis. As of today, only the application of the BCLC scoring system, which stratifies patients according to HCC staging and degree of liver disease in a process leading to a specific treatment, has shown the best results in terms of survival. 2007 S. Karger AG, Basel

Entities:  

Mesh：

Year:  2007        PMID： 17827957     DOI： 10.1159/000103902

Source DB:  PubMed          Journal:  Dig Dis        ISSN： 0257-2753            Impact factor:   2.404


  9 in total

1.  MRI versus 64-row MDCT for diagnosis of hepatocellular carcinoma.

Authors:  Michael Bernhard Pitton; Roman Kloeckner; Sascha Herber; Gerd Otto; Karl Friedrich Kreitner; Christoph Dueber
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

Review 2.  Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets.

Authors:  Tamara Severi; Hannah van Malenstein; Chris Verslype; Jos F van Pelt
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

3.  The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma.

Authors:  Jing Ai; Qingjuan Tang; Yanlin Wu; Yang Xu; Teng Feng; Ruiyu Zhou; Yi Chen; Xin Gao; Qingfeng Zhu; Xihua Yue; Qiuming Pan; Siyun Xu; Jing Li; Min Huang; Jennifer Daugherty-Holtrop; Yuanzheng He; H Eric Xu; Jia Fan; Jian Ding; Meiyu Geng
Journal:  J Natl Cancer Inst       Date:  2011-10-24       Impact factor: 13.506

4.  Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma.

Authors:  Guofeng Yu; Yingying Jing; Xingrui Kou; Fei Ye; Lu Gao; Qingmin Fan; Yang Yang; Qiudong Zhao; Rong Li; Mengchao Wu; Lixin Wei
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

5.  Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.

Authors:  Yeonhwa Song; Jaewoo Jang; Tae-Hoon Shin; Sang Mun Bae; Jin-Sun Kim; Kang Mo Kim; Seung-Jae Myung; Eun Kyung Choi; Haeng Ran Seo
Journal:  J Exp Clin Cancer Res       Date:  2017-03-03

6.  DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.

Authors:  Chao Zhou; Pu Wang; Mengtian Tu; Yi Huang; Fei Xiong; Yue Wu
Journal:  Biosci Rep       Date:  2019-07-10       Impact factor: 3.840

7.  Overexpression of Aristaless-Like Homeobox-4 Inhibits Proliferation, Invasion, and EMT in Hepatocellular Carcinoma Cells.

Authors:  Yao Shi; Xiaoke Sun; Xiafen He
Journal:  Oncol Res       Date:  2017-01-02       Impact factor: 5.574

8.  MicroRNA‑1271‑5p alleviates the malignant development of hepatitis B virus‑mediated liver cancer via binding to AQP5.

Authors:  Zhigang Li; Lin Ma; Lingling Di; Xutao Lin
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

9.  Twist expression promotes migration and invasion in hepatocellular carcinoma.

Authors:  Noriyuki Matsuo; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Naoki Ueda; Shigetomi Tanaka; Shinichi Nishina; Yutaka Nakanishi; Masayuki Uemura; Akinobu Takaki; Shinichiro Nakamura; Yoshiyuki Kobayashi; Kazuhiro Nouso; Takahito Yagi; Kazuhide Yamamoto
Journal:  BMC Cancer       Date:  2009-07-18       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.